Celcuity
IPOCelcuity Block Pam. Unlock Tomorrow
Public · Minneapolis, United States · Founded 2011 · $550.1M raised
- Headquarters
- Minneapolis, Minnesota
- Employees
- 51–200
- Founded
- 2011
- Business Model
- B2B
- Website
- celcuity.com
- Total Funding
- $550.1M
- Last Round
- $286.5M Convertible NoteAug 2025
- Rounds
- 5
- Type
- Public
About
Celcuity is a clinical-stage biotechnology company developing molecularly targeted therapies for solid tumor cancers driven by PI3K pathway dysregulation. Its lead candidate, gedatolisib, is a pan-PI3K/mTOR inhibitor being evaluated in Phase 3 trials for HR+/HER2- advanced breast cancer and has received an FDA NDA acceptance. The company also develops companion diagnostics to identify patients most likely to benefit from its precision oncology therapies.
Summary
Celcuity is a Biotech company based in Minneapolis, United States, founded in 2011. It has raised $550.1M in total across 5 rounds, most recently a $286.5M Convertible Note round in Aug 2025. Investors include NEA and Deerfield Management.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Aug 2025
Sign up to see all 5 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Global contract research organization providing comprehensive drug development and laboratory ser...